Shopping Cart 0
Cart Subtotal
AED 0

Fosun International Ltd (656) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Fosun International Ltd (Fosun) is an investment holding company, which offers asset management, insurance, industrial operations and strategic investment services. The company, through its subsidiaries, manufactures and sells pharmaceutical and healthcare products; undertakes property development; oil and gas exploration; mining and ore processing; and makes various other investments. Fosun offers life insurance and general insurance products, wealth management services, health management service, diagnosis products, and medical devices. It invests in the retail and wholesale of gold and jewelry, entertainment and tourism industries. The company has presence in China, Hong Kong and Portugal. Fosun is headquartered in Shanghai, China.

The company reported gross premiums written of CNY31,088.7 million in FY2017, a decline of 13.2% over FY2016. Its net premium written was CNY26,560 million in FY2017, a decline of 6% over FY2016.

Fosun International Ltd (656)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fosun International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Fosun International Ltd, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Novartis May Sell US Generic Pill Business 18

Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 20

Venture Financing 21

Ambrx Raises USD45 Million in Venture Financing 21

BeyondSpring Pharma Raises USD20 Million in Series A Financing 23

Saladax Biomedical Raises USD 23 Million In Series D Venture Financing 24

Private Equity 26

Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 26

Ardian May Sell Riemser Pharma for USD494.3 Million 28

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 30

Baring Private Equity Asia May Acquire Controlling Stake in Symbiotec Pharmalab from Actis Capital 31

Partnerships 33

AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 33

Arix Bioscience and Fosun International Enter into Agreement 34

Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 35

Marubeni to Form Joint Venture with Shanghai Fosun Pharma 36

Kite Pharma Forms Joint Venture with Fosun Pharma 37

Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 38

Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 39

Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 40

Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 41

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 42

Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 43

Licensing Agreements 44

Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 44

TB Alliance Enters Into Licensing Agreement With Fosun Pharma 45

Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 46

Equity Offering 47

Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 47

Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 49

Chindex to Raise USD38.2 Million in Private Placement of Shares 51

Fosun International Plans to Raise up to USD1.2 Billion in Public Offering of Shares 52

Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 53

Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 54

Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 55

Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 56

Nature's Sunshine Raises USD46 Million in Private Placement of Shares 57

Fosun International Announces Rights Offering Of Shares For Up To USD 668.4 Million 59

Shanghai Fosun Pharma Prices Private Placement Of Shares For USD 229.6 Million 60

Fosun International Completes IPO For USD 512 Million 61

Debt Offering 63

Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 63

Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 64

Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 65

Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 66

Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 67

Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 68

Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 69

Asset Transactions 70

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 70

Acquisition 71

Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 71

Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 72

Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 74

Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 75

Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 77

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 78

Fosun Increases Offer Price to Acquire Espirito Santo Saude for USD586 Million 79

Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To USD 304 Million 80

Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81

Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82

Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For USD 93 Million 83

Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84

Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85

Fosun Pharma Acquires 11% Stake In Shenzhen Belter For USD 7 Million 86

Fosun International Ltd-Key Competitors 87

Fosun International Ltd-Key Employees 88

Fosun International Ltd-Locations And Subsidiaries 89

Head Office 89

Other Locations & Subsidiaries 89

Recent Developments 91

Corporate Communications 91

Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World's Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 91

Appendix 94

Methodology 94

About GlobalData 94

Contact Us 94

Disclaimer 94


List Of Figure

List of Figures

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Fosun International Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fosun International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fosun International Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Novartis May Sell US Generic Pill Business 18

Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 20

Ambrx Raises USD45 Million in Venture Financing 21

BeyondSpring Pharma Raises USD20 Million in Series A Financing 23

Saladax Biomedical Raises USD 23 Million In Series D Venture Financing 24

Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 26

Ardian May Sell Riemser Pharma for USD494.3 Million 28

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 30

Baring Private Equity Asia May Acquire Controlling Stake in Symbiotec Pharmalab from Actis Capital 31

AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 33

Arix Bioscience and Fosun International Enter into Agreement 34

Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 35

Marubeni to Form Joint Venture with Shanghai Fosun Pharma 36

Kite Pharma Forms Joint Venture with Fosun Pharma 37

Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 38

Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 39

Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 40

Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 41

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 42

Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 43

Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 44

TB Alliance Enters Into Licensing Agreement With Fosun Pharma 45

Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 46

Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 47

Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 49

Chindex to Raise USD38.2 Million in Private Placement of Shares 51

Fosun International Plans to Raise up to USD1.2 Billion in Public Offering of Shares 52

Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 53

Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 54

Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 55

Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 56

Nature's Sunshine Raises USD46 Million in Private Placement of Shares 57

Fosun International Announces Rights Offering Of Shares For Up To USD 668.4 Million 59

Shanghai Fosun Pharma Prices Private Placement Of Shares For USD 229.6 Million 60

Fosun International Completes IPO For USD 512 Million 61

Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 63

Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 64

Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 65

Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 66

Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 67

Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 68

Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 69

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 70

Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 71

Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 72

Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 74

Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 75

Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 77

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 78

Fosun Increases Offer Price to Acquire Espirito Santo Saude for USD586 Million 79

Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To USD 304 Million 80

Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81

Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82

Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For USD 93 Million 83

Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84

Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85

Fosun Pharma Acquires 11% Stake In Shenzhen Belter For USD 7 Million 86

Fosun International Ltd, Key Competitors 87

Fosun International Ltd, Key Employees 88

Fosun International Ltd, Other Locations 89

Fosun International Ltd, Subsidiaries 89

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Fosun International Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Fosun International Ltd (Fosun) is an investment holding company, which offers asset management, insurance, industrial operations and strategic investment services. The company, through its subsidiaries, manufactures and sells pharmaceutical and healthcare products; undertakes property development; oil and gas exploration; mining and ore processing; and makes various other investments. Fosun offers life insurance and general insurance products, wealth management services, health management service, diagnosis products, and medical devices. It invests in the retail and wholesale of gold and jewelry, entertainment and tourism industries. The company has presence in China, Hong Kong and Portugal. Fosun is headquartered in Shanghai, China.

The company reported gross premiums written of CNY31,088.7 million in FY2017, a decline of 13.2% over FY2016. Its net premium written was CNY26,560 million in FY2017, a decline of 6% over FY2016.

Fosun International Ltd (656)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fosun International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Fosun International Ltd, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Novartis May Sell US Generic Pill Business 18

Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 20

Venture Financing 21

Ambrx Raises USD45 Million in Venture Financing 21

BeyondSpring Pharma Raises USD20 Million in Series A Financing 23

Saladax Biomedical Raises USD 23 Million In Series D Venture Financing 24

Private Equity 26

Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 26

Ardian May Sell Riemser Pharma for USD494.3 Million 28

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 30

Baring Private Equity Asia May Acquire Controlling Stake in Symbiotec Pharmalab from Actis Capital 31

Partnerships 33

AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 33

Arix Bioscience and Fosun International Enter into Agreement 34

Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 35

Marubeni to Form Joint Venture with Shanghai Fosun Pharma 36

Kite Pharma Forms Joint Venture with Fosun Pharma 37

Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 38

Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 39

Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 40

Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 41

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 42

Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 43

Licensing Agreements 44

Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 44

TB Alliance Enters Into Licensing Agreement With Fosun Pharma 45

Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 46

Equity Offering 47

Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 47

Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 49

Chindex to Raise USD38.2 Million in Private Placement of Shares 51

Fosun International Plans to Raise up to USD1.2 Billion in Public Offering of Shares 52

Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 53

Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 54

Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 55

Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 56

Nature's Sunshine Raises USD46 Million in Private Placement of Shares 57

Fosun International Announces Rights Offering Of Shares For Up To USD 668.4 Million 59

Shanghai Fosun Pharma Prices Private Placement Of Shares For USD 229.6 Million 60

Fosun International Completes IPO For USD 512 Million 61

Debt Offering 63

Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 63

Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 64

Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 65

Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 66

Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 67

Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 68

Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 69

Asset Transactions 70

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 70

Acquisition 71

Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 71

Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 72

Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 74

Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 75

Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 77

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 78

Fosun Increases Offer Price to Acquire Espirito Santo Saude for USD586 Million 79

Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To USD 304 Million 80

Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81

Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82

Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For USD 93 Million 83

Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84

Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85

Fosun Pharma Acquires 11% Stake In Shenzhen Belter For USD 7 Million 86

Fosun International Ltd-Key Competitors 87

Fosun International Ltd-Key Employees 88

Fosun International Ltd-Locations And Subsidiaries 89

Head Office 89

Other Locations & Subsidiaries 89

Recent Developments 91

Corporate Communications 91

Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World's Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 91

Appendix 94

Methodology 94

About GlobalData 94

Contact Us 94

Disclaimer 94


List Of Figure

List of Figures

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Fosun International Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fosun International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fosun International Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Fosun International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Novartis May Sell US Generic Pill Business 18

Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 20

Ambrx Raises USD45 Million in Venture Financing 21

BeyondSpring Pharma Raises USD20 Million in Series A Financing 23

Saladax Biomedical Raises USD 23 Million In Series D Venture Financing 24

Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 26

Ardian May Sell Riemser Pharma for USD494.3 Million 28

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 30

Baring Private Equity Asia May Acquire Controlling Stake in Symbiotec Pharmalab from Actis Capital 31

AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 33

Arix Bioscience and Fosun International Enter into Agreement 34

Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 35

Marubeni to Form Joint Venture with Shanghai Fosun Pharma 36

Kite Pharma Forms Joint Venture with Fosun Pharma 37

Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 38

Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 39

Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 40

Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 41

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 42

Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 43

Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 44

TB Alliance Enters Into Licensing Agreement With Fosun Pharma 45

Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 46

Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 47

Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 49

Chindex to Raise USD38.2 Million in Private Placement of Shares 51

Fosun International Plans to Raise up to USD1.2 Billion in Public Offering of Shares 52

Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 53

Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 54

Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 55

Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 56

Nature's Sunshine Raises USD46 Million in Private Placement of Shares 57

Fosun International Announces Rights Offering Of Shares For Up To USD 668.4 Million 59

Shanghai Fosun Pharma Prices Private Placement Of Shares For USD 229.6 Million 60

Fosun International Completes IPO For USD 512 Million 61

Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 63

Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 64

Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 65

Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 66

Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 67

Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 68

Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 69

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 70

Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 71

Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 72

Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 74

Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 75

Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 77

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 78

Fosun Increases Offer Price to Acquire Espirito Santo Saude for USD586 Million 79

Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To USD 304 Million 80

Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81

Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82

Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For USD 93 Million 83

Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84

Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85

Fosun Pharma Acquires 11% Stake In Shenzhen Belter For USD 7 Million 86

Fosun International Ltd, Key Competitors 87

Fosun International Ltd, Key Employees 88

Fosun International Ltd, Other Locations 89

Fosun International Ltd, Subsidiaries 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Fosun International Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.